These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Global view of cognate kinase activation by the human pyruvate dehydrogenase complex. Guevara EL; Yang L; Birkaya B; Zhou J; Nemeria NS; Patel MS; Jordan F Sci Rep; 2017 Feb; 7():42760. PubMed ID: 28230160 [TBL] [Abstract][Full Text] [Related]
6. Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases. Zhou X; Yu S; Su J; Sun L Int J Mol Sci; 2016 Mar; 17(3):340. PubMed ID: 26959013 [TBL] [Abstract][Full Text] [Related]
7. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors. Mann WR; Dragland CJ; Vinluan CC; Vedananda TR; Bell PA; Aicher TD Biochim Biophys Acta; 2000 Jul; 1480(1-2):283-92. PubMed ID: 11004568 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Sugden MC; Holness MJ Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):151-65. PubMed ID: 12476789 [TBL] [Abstract][Full Text] [Related]
10. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Kato M; Li J; Chuang JL; Chuang DT Structure; 2007 Aug; 15(8):992-1004. PubMed ID: 17683942 [TBL] [Abstract][Full Text] [Related]
11. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Moore JD; Staniszewska A; Shaw T; D'Alessandro J; Davis B; Surgenor A; Baker L; Matassova N; Murray J; Macias A; Brough P; Wood M; Mahon PC Oncotarget; 2014 Dec; 5(24):12862-76. PubMed ID: 25404640 [TBL] [Abstract][Full Text] [Related]
12. Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate. Li J; Kato M; Chuang DT J Biol Chem; 2009 Dec; 284(49):34458-67. PubMed ID: 19833728 [TBL] [Abstract][Full Text] [Related]
13. Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone. Holness MJ; Bulmer K; Smith ND; Sugden MC Biochem J; 2003 Feb; 369(Pt 3):687-95. PubMed ID: 12435272 [TBL] [Abstract][Full Text] [Related]
14. Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex. Tuganova A; Boulatnikov I; Popov KM Biochem J; 2002 Aug; 366(Pt 1):129-36. PubMed ID: 11978179 [TBL] [Abstract][Full Text] [Related]
16. Structural basis for the inhibition of PDK2 by novel ATP- and lipoyl-binding site targeting compounds. Kang J; Pagire HS; Kang D; Song YH; Lee IK; Lee KT; Park CJ; Ahn JH; Kim J Biochem Biophys Res Commun; 2020 Jun; 527(3):778-784. PubMed ID: 32444142 [TBL] [Abstract][Full Text] [Related]
17. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP. Bao H; Kasten SA; Yan X; Roche TE Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150 [TBL] [Abstract][Full Text] [Related]
18. Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. Kukimoto-Niino M; Tokmakov A; Terada T; Ohbayashi N; Fujimoto T; Gomi S; Shiromizu I; Kawamoto M; Matsusue T; Shirouzu M; Yokoyama S Acta Crystallogr D Biol Crystallogr; 2011 Sep; 67(Pt 9):763-73. PubMed ID: 21904029 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Pyruvate Dehydrogenase Kinase 2 Protects Against Hepatic Steatosis Through Modulation of Tricarboxylic Acid Cycle Anaplerosis and Ketogenesis. Go Y; Jeong JY; Jeoung NH; Jeon JH; Park BY; Kang HJ; Ha CM; Choi YK; Lee SJ; Ham HJ; Kim BG; Park KG; Park SY; Lee CH; Choi CS; Park TS; Lee WN; Harris RA; Lee IK Diabetes; 2016 Oct; 65(10):2876-87. PubMed ID: 27385159 [TBL] [Abstract][Full Text] [Related]
20. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity. Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]